SCHEMBL1424830

SCHEMBL1424830

CS(=O)(=O)N1CCC(NC(=O)c2ccc(F)cc2)CC1

nearest known ligand 0.67

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 2/20 0.67
KMT2A Q03164 6/20 0.65
MEN1 O00255 3/20 0.65
POLB P06746 1/20 0.65
RAB9A P51151 2/20 0.60
NPC1 O15118 1/20 0.60
LMNA P02545 1/20 0.59
L3MBTL1 Q9Y468 1/20 0.58
NPY5R Q15761 1/20 0.58
CCR5 P51681 1/20 0.56
SLC6A12 P48065 1/20 0.56
TMEM97 Q5BJF2 1/20 0.56
MCHR1 Q99705 1/20 0.56
SIGMAR1 Q99720 1/20 0.56
CTSB P07858 1/20 0.55
CTSS P25774 1/20 0.55
CTSK P43235 1/20 0.55
CTSC P53634 1/20 0.55
USP2 O75604 1/20 0.55
TSHR P16473 1/20 0.55

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12301960 0.87 LMNA (0.76) ALDH1A1KMT2AMEN1POLBRAB9A
SCHEMBL2299184 0.87 ALDH1A1 (0.69) ALDH1A1KMT2AMEN1POLBLMNA
SCHEMBL32679522 0.86 KMT2A (0.72) ALDH1A1KMT2AMEN1POLBLMNA
SCHEMBL6732134 0.85 POLB (0.88) ALDH1A1KMT2AMEN1POLBRAB9A
SCHEMBL4749226 0.82 NPC1 (0.67) KMT2AMEN1POLBRAB9ANPC1
SCHEMBL15772650 0.82 RORC (0.65) ALDH1A1KMT2AMEN1POLBRAB9A
SCHEMBL3958860 0.81 EPHX2 (0.76) KMT2AMEN1RAB9ANPC1LMNA
SCHEMBL3958253 0.80 NPC1 (0.63) KMT2AMEN1POLBRAB9ANPC1
Fk-962 SCHEMBL239762 0.80 KMT2A (0.69) KMT2AMEN1POLBRAB9ANPC1
SCHEMBL532160 0.80 RAB9A (0.83) KMT2AMEN1POLBRAB9ANPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1140836-B1 AMIDE COMPOUNDS ASTELLAS PHARMA INC (JP) 2011-03-23 EP disclosed
US-20040092528-A1 Agent for modulating excitatory synaptic transmission comprising a compound having alpha7 nicotinic acetylcholine receptor activation property FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2004-05-13 US disclosed
CN-1142910-C Amide compound ����ҩƷ��ҵ��ʽ���� 2004-03-24 CN disclosed
US-6710043-B1 POSSESS THE POTENTIATION OF THE CHOLINERGIC ACTIVITY FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2004-03-23 US disclosed
US-20040014745-A1 Amide compounds FUJISAWA PHARMACEUTICAL CO. LTD. (JP) 2004-01-22 US disclosed
EP-1315494-A1 AGENT FOR MODULATING EXCITATORY SYNAPTIC TRANSMISSION COMPRISING A COMPOUND HAVING ALPHA-7 NICOTINIC ACETYLCHOLINE RECEPTOR ACTIVATION PROPERTY FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2003-06-04 EP disclosed
EP-1235575-A2 AGENT FOR EXPRESSION OF LONG-TERM POTENTIATION OF SYNAPTIC TRANSMISSION COMPRISING COMPOUND HAVING BRAIN SOMATOSTATIN ACTIVATION PROPERTY FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2002-09-04 EP disclosed
WO-2002020016-A1 AGENT FOR MODULATING EXCITATORY SYNAPTIC TRANSMISSION COMPRISING A COMPOUND HAVING ALPHA α7 NICOTINIC ACETYLCHOLINE RECEPTOR ACTIVATION PROPERTY FUJISAWA PHARMACEUTICAL CO, LTD (JP) 2002-03-14 WO disclosed
CN-1336917-A Amide compounds FUJISAWA PHARMACEUTICAL CO (JP) 2002-02-20 CN disclosed
WO-2000072834-A9 AGENT FOR EXPRESSION OF LONG-TERM POTENTIATION OF SYNAPTIC TRANSMISSION COMPRISING COMPOUND HAVING BRAIN SOMATOSTATIN ACTIVATION PROPERTY FUJISAWA PHARMACEUTICAL CO (JP) 2001-12-20 WO disclosed
EP-1140836-A1 AMIDE COMPOUNDS FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2001-10-10 EP disclosed
WO-2000072834-A2 AGENT FOR EXPRESSION OF LONG-TERM POTENTIATION OF SYNAPTIC TRANSMISSION COMPRISING COMPOUND HAVING BRAIN SOMATOSTATIN ACTIVATION PROPERTY FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2000-12-07 WO disclosed
WO-2000042011-A1 AMIDE COMPOUNDS FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2000-07-20 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040014745-A1 Amide compounds CHRM1, CHRM2, CHRNE ALDH1A1 1088/4885KMT2A 1224/4885MEN1 1551/4885
US-20040092528-A1 Agent for modulating excitatory synaptic transmission comprising a compound having alpha7 nicotinic acetylcholine receptor activation property CHRNA7, CHRNA5, CHRNA10 ALDH1A1 2011/4885KMT2A 4093/4885MEN1 1925/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.